Most cited papers from Chiba Cancer Center

Chiba Cancer Center

What are the most cited papers from Chiba Cancer Center?

The most cited paper from Chiba Cancer Center is "Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma" (Robert John Motzer et al., 2015), with 5,972 citations. Next come "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial" (2,505) and "Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial" (2,317).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 226 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access	25 Sep 2015	5,972
2	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Hansjochen Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology	17 Sep 2014	2,505
3	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang et al. · The Lancet Open access	12 Oct 2017	2,317
4	Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases Hidefumi Aoyama, Hiroki Shirato, Masao Tago et al. · JAMA	6 Jun 2006	2,226
5	ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis Kaori Ishikawa, Keizo Takenaga, Miho Akimoto et al. · Science Open access	3 Apr 2008	1,483
6	EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors Young Lim Choi, Manabu Soda, Yoshihiro Yamashita et al. · New England Journal of Medicine Open access	27 Oct 2010	1,192
7	Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi et al. · The Lancet	3 Jun 2016	1,145
8	Oncogenic mutations of ALK kinase in neuroblastoma Yuyan Chen, Junko Takita, Young Lim Choi et al. · Nature	Oct 2008	927
9	Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments Shogo Kumagai et al. · Cancer Cell Open access	28 Jan 2022	890
10	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies Shogo Kumagai et al. · Nature Immunology	31 Aug 2020	824
11	Role of p53 in Cell Death and Human Cancers Toshinori Ozaki, Akira Nakagawara · Cancers Open access	3 Mar 2011	755
12	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study Takashi Seto, Terufumi Kato, Makoto Nishio et al. · The Lancet Oncology	27 Aug 2014	754
13	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study Emmanuel S. Antonarakis et al. · Journal of Clinical Oncology Open access	27 Nov 2019	740
14	Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Ken Tokunaga, Yoshikazu Nakamura, K Sakata et al. · PubMed	Nov 1987	552
15	Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer Yasuhide Yamada et al. · Annals of Oncology Open access	15 Oct 2014	546
16	Nucleotide sequence of a full-length cDNA for mousecytosketetal β-actin raRNA K. ToIcunaga, Hiroki Taniguchi, Kiyoe Yoda et al. · Nucleic Acids Research Open access	1986	545
17	Cloning and functional analysis of human p51, which structurally and functionally resembles p53 Motonobu Osada, Mai Ohba, Chikashi Kawahara et al. · Nature Medicine	Jul 1998	531
18	ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms Yoshihiro Onouchi et al. · Nature Genetics Open access	16 Dec 2007	525
19	Trk receptor tyrosine kinases: A bridge between cancer and neural development Akira Nakagawara · Cancer Letters	Aug 2001	499
20	Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212) Shin Fujita et al. · Annals of Surgery Open access	11 Mar 2017	449
21	International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee Peter F. Ambros, I.M. Ambros, G M Brodeur et al. · British Journal of Cancer Open access	28 Apr 2009	409
22	High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer Hideaki Shimada, Nobuhiro Takiguchi, Osamu Kainuma et al. · Gastric Cancer Open access	Aug 2010	390
23	High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma Ashraful Islam, Hajime Kageyama, Naoyuki Takada et al. · Oncogene	3 Feb 2000	388
24	Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial Toshihiro Kudo, Yasuo Hamamoto, Ken Kato et al. · The Lancet Oncology	14 Mar 2017	386
25	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies Yoshiaki Nakamura et al. · Nature Medicine	5 Oct 2020	380
26	Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut Kazuhiko Kakihana, Yuki Fujioka, Wataru Suda et al. · Blood Open access	26 Jul 2016	371
27	Adjuvant chemotherapy for resected early-stage non-small cell lung cancer Sarah Burdett et al. · Cochrane Database of Systematic Reviews Open access	2 Mar 2015	369
28	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial Robert John Motzer et al. · Cancer Open access	16 Jul 2020	342
29	Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial Chigusa Morizane et al. · Annals of Oncology Open access	26 Sep 2019	338
30	Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) Narikazu Boku, Min‐Hee Ryu, Ken Kato et al. · Annals of Oncology Open access	14 Dec 2018	326
31	Immune evasion through mitochondrial transfer in the tumour microenvironment Hideki Ikeda et al. · Nature Open access	22 Jan 2025	320
32	Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies Shohei Koyama, Hiroyoshi Nishikawa · Journal for ImmunoTherapy of Cancer Open access	Jul 2021	318
33	Antitumour immunity regulated by aberrant ERBB family signalling Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa · Nature reviews. Cancer Review	18 Jan 2021	305
34	Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study Masatoshi Kudo, Kazuomi Ueshima, Stephan Chan et al. · Cancers Open access	31 Jul 2019	300
35	Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study) Kenichi Nakamura, Ken Kato, Hiroyasu Igaki et al. · Japanese Journal of Clinical Oncology	26 Apr 2013	299
36	Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer Eri Sugiyama, Yosuke Togashi, Yoshiko Takeuchi et al. · Science Immunology	3 Jan 2020	294
37	Clinicopathological Features and Prognosis of Mucinous Cystic Neoplasm With Ovarian-Type Stroma Kenji Yamao et al. · Pancreas	5 Oct 2010	293
38	Transcriptional activation of early‐response genes by hydrogen peroxide in a mouse osteoblastic cell line Kiyoshi Nose, Motoko Shibanuma, Keishi Kikuchi et al. · European Journal of Biochemistry	Oct 1991	291
39	Salivary gland malignant myoepithelioma Toshitaka Nagao, Isamu Sugano, Yasuo Ishida et al. · Cancer Open access	Oct 1998	287
40	Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) K. Yamazaki et al. · Annals of Oncology Open access	14 May 2016	285
41	Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer Jun Watanabe et al. · JAMA Open access	18 Apr 2023	281
42	Single-cell sequencing techniques from individual to multiomics analyses Yukie Kashima, Yoshitaka Sakamoto, Keiya Kaneko et al. · Experimental & Molecular Medicine Open access	Sep 2020	280
43	Activation of AMP-activated Protein Kinase Induces p53-dependent Apoptotic Cell Death in Response to Energetic Stress Rintaro Okoshi, Toshinori Ozaki, Hideki Yamamoto et al. · Journal of Biological Chemistry Open access	5 Dec 2007	278
44	An Asian variant of intravascular large B‐cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B‐cell lymphoma associated with haemophagocytic syndrome Takuhei Murase, Shigeo Nakamura, Kiyotaka Kawauchi et al. · British Journal of Haematology	Dec 2000	275
45	Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma Hideaki Takahashi, Yuichiro Tada, Takashi Saotome et al. · Journal of Clinical Oncology	19 Nov 2018	269
46	An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells Shogo Kumagai, Yosuke Togashi, Chika Sakai et al. · Immunity Open access	Jul 2020	267
47	Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation Kiyohiro Ando, Toshinori Ozaki, Hideki Yamamoto et al. · Journal of Biological Chemistry Open access	Jun 2004	262
48	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma Toshihiko Iuchi, Masato Shingyoji, Tsukasa Sakaida et al. · Lung Cancer	28 Aug 2013	261
49	Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease Masaomi Iyo, Hiroki Namba, Kiyoshi Fukushi et al. · The Lancet	Jun 1997	261
50	Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Hideo Kimura, Hiroyasu Esumi · Acta Biochimica Polonica Open access	31 Mar 2003	260

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.